Interpretation of the latest policy on whether adagrasib (Krazati) can be reimbursed and included in the medical insurance directory

Adagrasiib (Krazati) is an oral targeted drug mainly used to treat patients with KRAS G12C mutation-positive non-small cell lung cancer (NSCLC). The drug inhibits the activity of KRAS mutated protein and blocks tumor signaling pathways, thereby delaying tumor development. As of2025, adagrasib has not yet been officially launched in China. Therefore, domestic patients cannot purchase it directly through hospitals or pharmacies and can only rely on overseas channels to obtain it.

Since adagrasib is not marketed in China and has not been included in the national medical insurance directory, domestic patients cannot enjoy medical insurance reimbursement when using the drug. If patients purchase drugs through overseas channels, they need to bear all costs themselves, which makes the financial burden of drugs greater. Especially the American version of the original drug, the price per box is as high as hundreds of thousands of yuan, which is a considerable expense for ordinary patients.

In order to reduce the cost of medication for patients, generic drugs of adagrasibu have been launched in some overseas markets. For example, the price of generic drugs in the Laos market is about more than 3,000 yuan per box, and the ingredients of the drugs are basically the same as the original drugs. Compared with original drugs, these generic drugs are more affordable, providing viable alternatives for patients who need to use the drugs while reducing financial pressure.

With the gradual improvement of domestic drug approval and import policies, adagrasib is expected to be launched in China and entered into the medical insurance catalog in the future, at which time patients can enjoy a certain proportion of medical insurance reimbursement. Prior to this, patients are advised to obtain drugs through formal overseas channels and use them under the guidance of professional doctors. At the same time, paying attention to the dynamics of drug launches and medical insurance policies will help timely plan medication plans and ensure treatment safety and affordability.

Reference link:https://www.drugs.com